NEW YORK – While Illumina has taken a hit to revenues due to the COVID-19 pandemic, the firm sees an expanded total addressable market in the new coronavirus normal.
"If you had talked to us in January, or certainly by December or before, we really would have talked to you much more about the clinical opportunity in oncology and reproductive health, but not a lot about infectious disease," Illumina CEO Francis deSouza told investors on a Thursday conference call following the release of the firm's second quarter financial results.